Bioventus Inc. (NASDAQ:BVS) Stock Rated “Moderate Buy” by Sell-Side Analysts

Shares of Bioventus Inc. (NASDAQ:BVS) have been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $16.80.

Several equities research analysts have weighed in on BVS shares. Barrington Research set a $18.00 target price on Bioventus in a research note on Thursday, August 6th. Weiss Ratings upgraded Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, August 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 price target on shares of Bioventus in a report on Monday, August 17th. Canaccord Genuity Group upped their price objective on Bioventus from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Monday, August 17th. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Bioventus in a research note on Thursday, August 6th.

Bioventus Trading Down 2.4%

Shares of NASDAQ:BVS opened at $13.13 on Monday. The company’s fifty day simple moving average is $13.70 and its 200 day simple moving average is $11.19. Bioventus has a 12 month low of $6.37 and a 12 month high of $15.89. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of 17.05, a PEG ratio of 1.71 and a beta of 0.64. The company has a quick ratio of 1.17, a current ratio of 1.69 and a debt-to-equity ratio of 0.83.

Bioventus (NASDAQ:BVS) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.22 EPS for the quarter, meeting the consensus estimate of $0.22. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. The firm had revenue of $153.21 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, research analysts forecast that Bioventus will post 0.79 EPS for the current fiscal year.

Institutional Trading of Bioventus

A number of institutional investors and hedge funds have recently bought and sold shares of BVS. Caitong International Asset Management Co. Ltd increased its stake in Bioventus by 17,156.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after purchasing an additional 5,490 shares in the last quarter. Diversified Trust Co acquired a new stake in Bioventus in the 1st quarter valued at $100,000. State of Wyoming increased its stake in Bioventus by 45.5% during the 4th quarter. State of Wyoming now owns 38,357 shares of the company’s stock valued at $285,000 after purchasing an additional 11,989 shares in the last quarter. Quantinno Capital Management LP increased its stake in Bioventus by 119.6% during the 1st quarter. Quantinno Capital Management LP now owns 72,023 shares of the company’s stock valued at $658,000 after purchasing an additional 39,222 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in Bioventus by 11.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 79,913 shares of the company’s stock worth $730,000 after buying an additional 8,225 shares during the last quarter. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Bioventus Company Profile

Bioventus Inc (NASDAQ:BVS) is a medical device company focused on therapies for musculoskeletal conditions. The company develops, manufactures and commercializes products intended to support bone healing, improve joint health and assist with surgical and rehabilitative care.

Its portfolio includes bone-healing systems such as EXOGEN, an ultrasound device used to support fracture healing, as well as osteoarthritis treatments including DUROLANE and GELSYN-3 hyaluronic acid injections. Bioventus also offers surgical technologies through its Misonix business, including ultrasonic systems used in procedures involving soft tissue and bone, and rehabilitation and neurostimulation products through its Bioness business.

Bioventus was formed in 2011 following the separation of a bone-healing business from Smith & Nephew and is headquartered in Durham, North Carolina.